Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 6/20 | 0.65 |
| ▸ | POLB | P06746 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069530 | 0.85 | ALDH1A1 (0.64) | ALDH1A1KDM4ELMNAGAAPOLB | |
| SCHEMBL20147405 | 0.83 | MEN1 (0.71) | ALDH1A1KDM4ELMNAGAAPOLB | |
| SCHEMBL28610882 | 0.73 | ALDH1A1 (0.53) | ALDH1A1KDM4ELMNAGAAPOLB | |
| SCHEMBL19832548 | 0.73 | SIGMAR1 (0.61) | ALDH1A1KDM4ELMNAGAAPOLB | |
| SCHEMBL24137999 | 0.72 | KDM4E (0.47) | ALDH1A1KDM4ELMNAGAAPOLB | |
| SCHEMBL18234102 | 0.72 | SIGMAR1 (0.74) | ALDH1A1KDM4EPOLBMEN1KMT2A | |
| SCHEMBL29324731 | 0.69 | SIGMAR1 (0.86) | — | |
| SCHEMBL17760993 | 0.69 | ALDH1A1 (0.46) | ALDH1A1KDM4ELMNAGAAPOLB | |
| SCHEMBL29002710 | 0.68 | SMN1; SMN2 (0.45) | ALDH1A1KDM4ELMNAGAAPOLB | |
| SCHEMBL5995214 | 0.68 | POLB (0.77) | ALDH1A1KDM4ELMNAGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | ALDH1A1 2547/4885KDM4E 547/4885LMNA 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.